One-Of-A-Kind Test That Targets the Majority of Cancer Population Currently Not Qualified for Precision Medicine

Los Angeles, Cali. -- OncoDxRx announced the completion of validation of its one-of-a-kind assay for patients with non-small cell lung cancer (NSCLC) who currently are excluded from targeted therapy or immunotherapy (precision medicine).

Not every cancer patient is qualified for precision medicine. Only about 20-30% of cancer patients are eligible after genomic testing, leaving the majority of patients with the only option of chemotherapy. This also leaves doctors with no full-knowledge of current anti-cancer drug efficacy before planning treatment regimens -- ultimately missing the best treatment option.

OncoDxRx’s patent-pending, transformative diagnostic technology, PGA (for Patient-derived Gene expression-informed Anti-cancer drug efficacy), can provide comprehensive anti-cancer drug efficacy data within 5 days and improve the clinical-benefit rate for cancer patients.

Therapies that follow PGA results have provided better outcomes for patients when they exhibit advanced tumors that are refractory to standard treatment, OncoDxRx said.

The firm added that PGA’s unprecedented potential of selecting optimal treatment regimen among hundreds of anti-cancer drugs for individual patients based on patients’ own gene expression profiles will impact the cancer clinical therapeutics profoundly.

The liquid biopsy basis for the PGA test also makes it vital for lung cancer patients in whom repeated tumor biopsy is practically not possible.